KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to -$15.0 million.

  • Arbutus Biopharma's Net Cash Flow rose 5155.59% to -$15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year decrease of 16578.19%. This contributed to the annual value of $10.1 million for FY2024, which is 32351.64% up from last year.
  • Arbutus Biopharma's Net Cash Flow amounted to -$15.0 million in Q3 2025, which was up 5155.59% from $315000.0 recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Net Cash Flow high stood at $46.9 million for Q3 2021, and its period low was -$48.5 million during Q2 2021.
  • Moreover, its 5-year median value for Net Cash Flow was $742000.0 (2025), whereas its average is -$1.6 million.
  • Data for Arbutus Biopharma's Net Cash Flow shows a peak YoY increase of 60649.54% (in 2021) and a maximum YoY decrease of 34817.96% (in 2021) over the last 5 years.
  • Over the past 5 years, Arbutus Biopharma's Net Cash Flow (Quarter) stood at $31.4 million in 2021, then tumbled by 78.42% to $6.8 million in 2022, then grew by 28.98% to $8.7 million in 2023, then plummeted by 48.32% to $4.5 million in 2024, then tumbled by 431.9% to -$15.0 million in 2025.
  • Its Net Cash Flow was -$15.0 million in Q3 2025, compared to $315000.0 in Q2 2025 and $742000.0 in Q1 2025.